再生医療市場の市場規模、シェア、動向分析レポート：製品別、治療カテゴリー別、地域別、セグメント予測、2024年～2030年

再生医療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の再生医療市場規模は2024年から2030年にかけて16.79%のCAGRで拡大し、2030年には900億1,000万米ドルに達すると予測されています。

強力なパイプラインの存在は、再生医療市場の主要促進要因の一つです。企業は自社製品を最新技術でアップグレードし、顧客のアンメットニーズを満たすために研究開発に多額の投資を行っています。

さらに、疾患治療療法に対する需要の高まりを受けて、企業はゲノムレベルで疾患の原因をターゲットとする遺伝子療法の研究開発を加速させることに注力しています。PhRMAが発表したデータによると、米国のパイプライン・プログラム（第I～III相試験）にある細胞・遺伝子治療薬は、2018年の289件から2019年には362件に増加しました。これは単年で25％の増加です。この分野における継続的な進歩は、再生医療の需要をさらに押し上げると思われます。

幹細胞、組織工学、ナノテクノロジーなどの技術の進歩により、再生医療は非常に学際的な分野となっています。幹細胞は未分化細胞であり、軟骨、腱、靭帯、筋肉、骨などの他の細胞を修復・再生する能力を持つ。2021年7月、ブルーロック・セラピューティクス社は、多能性幹細胞由来のドーパミン作動性ニューロン治療薬DA01について、進行性パーキンソン病治療薬としてFDAの承認を取得しました。この承認により、同社の製品ラインアップが拡大することが期待されます。

複数の主要企業が新製品開発や戦略的提携などの戦略的イニシアチブをとっており、再生医療市場の成長に貢献しています。例えば、2021年11月にアステラス製薬はPantherna Therapeutics GmbHとmRNAベースの再生医療を研究する契約を締結しました。この構想では、アステラス製薬の高い創薬能力とPanthernaの最先端のmRNAプラットフォームが活用され、新たなプログラム開発のための研究が推進されます。また、2021年5月、バイエルAGはセンティ・バイオ社と遺伝子回路を組み込んだ再生医療向け細胞治療開発に関する提携を締結しました。

再生医療市場レポートハイライト

• 高齢化社会の進展と加齢性疾患の増加により、治療薬分野が再生医療市場で最大のシェアを占めています。
• 幹細胞や組織ベースの再生療法に関する臨床試験の増加と再生療法に対する需要の増加は、市場の成長にプラスの影響を与えると予想されます。
• 幹細胞および前駆細胞をベースとした治療法は、研究開発分野への巨額の投資と幹細胞バンクの増加により、大きな成長が見込まれます。
• 北米は、幹細胞ベースの治療法の研究開発に取り組んでいる研究機関や大学が数多く存在することから、2023年の市場規模は北米が圧倒的でした。
• アジア太平洋地域は、ヘルスケア産業における細胞ベースの急速な導入により、今後数年間で最も急速な成長が見込まれています。
• 治療カテゴリー別では、世界のがん患者の増加により、より良い解決策への需要が高まっているため、2023年にはがん分野がこの分野を支配します。強固なパイプラインの増加が市場成長を牽引しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場動向と展望
• 市場力学
  • 強力なパイプラインと多数の臨床試験の存在
  • 再生医療による高い経済効果
  • 再生医療における遺伝子治療の新たな応用
  • 再生医療の開発を支援するための政府および民間資金の増加
  • 再生医療における技術の進歩（幹細胞、組織工学、ナノテクノロジー）
  • 再生医療の開発と商業化を加速するための戦略的パートナーシップの増加
  • 慢性疾患および遺伝性疾患、変性疾患、骨および関節疾患の有病率の上昇により、再生治療の需要が増加
• 市場抑制要因分析
  • 高額な治療費
  • 幹細胞、組織工学、再生医療に関する規制問題
• 事業環境分析
  • PESTEL分析
  • ポーターのファイブフォース分析
  • COVID-19感染症の影響分析

第4章 製品ビジネス分析

• 世界の再生医療市場：製品変動分析
• 治療学
  • 治療薬市場、2018年～2030年
  • 一次細胞ベースの治療法
  • 幹細胞および前駆細胞に基づく治療法
  • 細胞ベースの免疫療法
  • 遺伝子治療
• ツール
  • ツール市場、2018年～2030年
• バンク
  • バンク市場、2018年～2030年
• サービス
  • サービス市場、2018年～2030年

第5章 治療カテゴリーのビジネス分析

• 世界の再生医療市場：治療カテゴリーの変動分析
• 皮膚科
• 筋骨格系
• 免疫学と炎症
• 腫瘍学
• 心臓血管
• 眼科
• その他

第6章 地域ビジネス分析

• 地域別の世界の再生医療市場シェア、2022年と2030年
• 北米
  • 北米再生医療市場、2018年～2030年
  • 米国
  • カナダ
• 欧州
  • 欧州再生医療市場、2018年～2030年
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • アジア太平洋の再生医療市場、2018年～2030年
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • ラテンアメリカの再生医療市場、2018年から2030年
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 中東・アフリカ再生医療市場、2018年～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 企業の分類
• 戦略マッピング
• Company Market/Position Share Analysis, 2022年
• 企業プロファイル・一覧表
  • AstraZeneca plc.
  • F. Hoffmann-La Roche Ltd.
  • Integra Lifesciences Corp.
  • Astellas Pharma, Inc.
  • Cook Biotech, Inc.
  • Bayer AG
  • Pfizer, Inc.
  • Merck KGaA
  • Abbott
  • Vericel Corp.
  • Novartis AG
  • GlaxoSmithKline

List of Tables

• Table 1 List Of Secondary Sources
• Table 2 List Of Abbreviations
• Table 3 Global Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 4 Global Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 5 North America Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
• Table 6 North America Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 7 North America Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 8 U.S. Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 9 U.S. Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 10 Canada Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 11 Canada Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 12 Europe Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
• Table 13 Europe Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 14 Europe Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 15 Germany Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 16 Germany Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 17 U.K. Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 18 U.K. Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 19 France Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 20 France Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 21 Italy Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 22 Italy Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 23 Spain Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 24 Spain Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 25 Denmark Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 26 Denmark Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 27 Norway Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 28 Norway Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 29 Sweden Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 30 Sweden Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 31 Asia Pacific Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
• Table 32 Asia Pacific Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 33 Asia Pacific Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 34 China Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 35 China Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 36 Japan Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 37 Japan Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 38 India Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 39 India Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 40 Australia Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 41 Australia Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 42 South Korea Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 43 South Korea Regenerative Medicine Market, by services, 2018 - 2030 (USD Million)
• Table 44 Thailand Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 45 Thailand Regenerative Medicine Market, by services, 2018 - 2030 (USD Million)
• Table 46 Latin America Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
• Table 47 Latin America Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 48 Latin America Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 49 Brazil Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 50 Brazil Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 51 Mexico Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 52 Mexico Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 53 Argentina Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 54 Argentina Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 55 Middle East & Africa Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
• Table 56 Middle East & Africa Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 57 Middle East & Africa Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 58 South Africa Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 59 South Africa Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 60 Saudi Arabia Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 61 Saudi Arabia Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 62 UAE Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 63 UAE Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 64 Kuwait Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
• Table 65 Kuwait Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
• Table 66 Participant's Overview
• Table 67 Financial Performance
• Table 68 Key Companies Undergoing Expansions
• Table 69 Key Companies Undergoing Acquisitions
• Table 70 Key Companies Undergoing Collaborations
• Table 71 Key Companies Launching New Products/Services
• Table 72 Key Companies Undergoing Partnerships
• Table 73 Key Companies Undertaking Other Strategies

List of Figures

• Fig. 1 Market Others process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary Others pattern
• Fig. 4 Market Others approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Market summary, 2023 (USD Million)
• Fig. 9 Market segmentation & scope
• Fig. 10 Market driver impact
• Fig. 11 Market restraint impact
• Fig. 12 Penetration & growth prospect mapping
• Fig. 13 Porter's analysis
• Fig. 14 SWOT analysis
• Fig. 15 Global regenerative medicine therapeutics market, 2018 - 2030 (USD Million)
• Fig. 16 Global primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
• Fig. 17 Global dermatology primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
• Fig. 18 Global musculoskeletal primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
• Fig. 19 Global surgical primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
• Fig. 20 Global dental primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
• Fig. 21 Global other primary cell-based therapeutics market, 2018 - 2030 (USD Million)
• Fig. 22 Global autologous stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
• Fig. 23 Global autologous stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
• Fig. 24 Global allogeneic stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
• Fig. 25 Global other stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
• Fig. 26 Global cell-based immunotherapies market, 2018 - 2030 (USD Million)
• Fig. 27 Global gene therapies market, 2018 - 2030 (USD Million)
• Fig. 28 Global regenerative medicines tools, 2018 - 2030 (USD Million)
• Fig. 29 Global banks market for regenerative medicine, 2018 - 2030 (USD Million)
• Fig. 30 Global regenerative medicine services market, 2018 - 2030 (USD Million)
• Fig. 31 Regenerative medicine market: Therapeutic category outlook and key takeaways
• Fig. 32 Regenerative medicine market: Therapeutic category movement analysis (USD Million)
• Fig. 33 Global dermatological therapeutics category market, 2018 - 2030 (USD Million)
• Fig. 34 Global musculoskeletal therapeutics category market, 2018 - 2030 (USD Million)
• Fig. 35 Global immunology & inflammation therapeutics category market, 2018 - 2030 (USD Million)
• Fig. 36 Global oncology therapeutics category market, 2018 - 2030 (USD Million)
• Fig. 37 Global cardiovascular therapeutics category market, 2018 - 2030 (USD Million)
• Fig. 38 Global ophthalmology therapeutics market, 2018 - 2030 (USD Million)
• Fig. 39 Global other therapeutics category market, 2018 - 2030 (USD Million)
• Fig. 40 Global Regenerative Medicine Market: Regional outlook and key takeaways
• Fig. 41 North America Regenerative Medicine Market, 2018 - 2030 (USD million)
• Fig. 42 U.S. key country dynamics
• Fig. 43 U.S. Regenerative Medicine Market, 2018 - 2030 (USD million)
• Fig. 44 Canada key country dynamics
• Fig. 45 Canada Regenerative Medicine Market, 2018 - 2030 (USD million)
• Fig. 46 Europe Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 47 Germany key country dynamics
• Fig. 48 Germany Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 49 France key country dynamics
• Fig. 50 France Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 51 U.K. key country dynamics
• Fig. 52 U.K. Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 53 Italy key country dynamics
• Fig. 54 Italy Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 55 Spain key country dynamics
• Fig. 56 Spain Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 57 Denmark key country dynamics
• Fig. 58 Denmark Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 59 Sweden key country dynamics
• Fig. 60 Sweden Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 61 Norway key country dynamics
• Fig. 62 Norway Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 63 Asia-Pacific Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 64 China key country dynamics
• Fig. 65 China Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 66 India key country dynamics
• Fig. 67 India Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 68 South Korea key country dynamics
• Fig. 69 South Korea Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 70 Japan key country dynamics
• Fig. 71 Japan Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 72 Australia key country dynamics
• Fig. 73 Australia Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 74 Thailand key country dynamics
• Fig. 75 Thailand Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 76 Latin America Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 77 Brazil key country dynamics
• Fig. 78 Brazil Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 79 Mexico key country dynamics
• Fig. 80 Mexico Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 81 Argentina key country dynamics
• Fig. 82 Argentina Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 83 MEA Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 84 South Africa key country dynamics
• Fig. 85 South Africa Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 86 Saudi Arabia key country dynamics
• Fig. 87 Saudi Arabia Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 88 UAE key country dynamics
• Fig. 89 UAE Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 90 Kuwait key country dynamics
• Fig. 91 Kuwait Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 92 Market participant categorization
• Fig. 93 Regenerative Medicine Market share analysis, 2023
• Fig. 94 Strategy framework

Regenerative Medicine Market Growth & Trends:

The global regenerative medicine market size is expected to reach USD 90.01 billion by 2030, expanding at a CAGR of 16.79% from 2024 to 2030, according to a new report by Grand View Research, Inc. The presence of a strong pipeline is one of the major drivers in the regenerative medicine market. Companies invest heavily in R&D to upgrade their products with the latest technology and fulfil the unmet needs of their customers.

Furthermore, with the increasing demand for disease treatment therapies, companies have focused their efforts to accelerate R&D for gene therapies that target the cause of disease at a genomic level. The cell and gene therapies in the U.S. pipeline programs (Phase I-III trials) grew from 289 in 2018 to 362 by 2019 according to the data published by PhRMA,. This represents an increase of 25% in a single year. Continuous advancements in this field would further boost the demand for regenerative medicines.

Technological advancements such as stem cells, tissue engineering, and nanotechnology has made regenerative medicines a highly interdisciplinary in field. Stem cells are undifferentiated cells, which have the capability to repair and/or regenerate into other cells such as cartilage, tendons, ligaments, muscle, and bones. In July 2021, BlueRock Therapeutics received FDA approval for its pluripotent stem cell-derived dopaminergic neuron therapy, DA01, for advanced Parkinson's disease treatment. This approval was expected to expand the company's offerings.

Several key players are taking strategic initiatives such as new product development, strategic alliances, and others have contributed to the regenerative medicine market growth. For instance, in November 2021, Astellas Pharma, Inc. entered into an agreement with Pantherna Therapeutics GmbH to study mRNA-based regenerative medicine. Under this initiative, Astellas' high drug discovery capabilities and Pantherna's state-of-the-art mRNA platform will be used to promote research on developing a new program. In addition, in May 2021, Bayer AG entered into a collaboration with Senti Bio for gene circuit-engineered cell therapies development for regenerative medicine.

Regenerative Medicine Market Report Highlights:

• The therapeutics segment held the largest share in the regenerative medicine market, owing to the growing aging population coupled with an increasing rate of age-related disorders.
• The rise in a number of clinical trials for stem cell and tissue-based regenerative therapies along with an increase in demand for regenerative therapies is expected to positively influence the growth of the market.
• Stem cell and progenitor cell-based therapies are projected to witness significant growth owing to huge investments in the R&D space and a growing number of stem cell banks
• North America dominated the market in 2023 owing to the presence of a significant number of research organizations and universities which are working on R&D of stem cell-based therapies.
• Asia Pacific is anticipated to witness the fastest growth in the coming years owing to the rapid adoption of cell-based methods in the healthcare industry.
• By therapeutic category, the oncology segment dominated the segment in 2023 owing to the increasing cases of cancer globally which is rising the demand for better solutions. The growing number of robust pipelines is driving the market growth.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Information analysis
  • 1.2.2. Market formulation & data visualization
  • 1.2.3. Data validation & publishing
• 1.3. Information Procurement
  • 1.3.1. Primary Others
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Market Model
• 1.7. Objectives
  • 1.7.1. Objective 1
  • 1.7.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Presence of a strong pipeline and a large number of clinical trials
  • 3.3.2. High economic impact of regenerative medicine
  • 3.3.3. Emerging applications of gene therapy in regenerative medicine
  • 3.3.4. Increasing government & private funding to support the development of regenerative medicine
  • 3.3.5. Technological advancements in regenerative medicine (stem cell, tissue engineering, and nanotechnology)
  • 3.3.6. Increase in strategic partnerships to accelerate development & commercialization of regenerative medicines
  • 3.3.7. Rising prevalence of chronic diseases & genetic disorders, degenerative diseases, and bone & joint diseases leading to rise in demand for regenerative treatments
• 3.4. Market Restraint Analysis
  • 3.4.1. High cost of treatment
  • 3.4.2. Regulatory issues pertaining to stem cells, tissues engineering, and regenerative medicines
• 3.5. Business Environment Analysis
  • 3.5.1. PESTEL Analysis
  • 3.5.2. Porter's Five Forces Analysis
  • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis

• 4.1. Global Regenerative Medicine Market: Product Movement Analysis
• 4.2. Therapeutics
  • 4.2.1. Therapeutics Market, 2018 - 2030 (USD Million)
  • 4.2.2. Primary Cell-Based Therapeutics
    • 4.2.2.1. Primary Cell-Based Therapeutics Market, 2018 - 2030 (USD Million)
    • 4.2.2.2. Dermatology
    • 4.2.2.2.1. Dermatology Market, 2018 - 2030 (USD Million)
    • 4.2.2.3. Musculoskeletal
    • 4.2.2.3.1. Musculoskeletal Market, 2018 - 2030 (USD Million)
    • 4.2.2.4. Surgical
    • 4.2.2.4.1. Surgical Market, 2018 - 2030 (USD Million)
    • 4.2.2.5. Dental
    • 4.2.2.5.1. Dental Market, 2018 - 2030 (USD Million)
    • 4.2.2.6. Others
    • 4.2.2.6.1. Others Market, 2018 - 2030 (USD Million)
  • 4.2.3. Stem Cell & Progenitor Cell-based therapeutics
    • 4.2.3.1. Stem Cell & Progenitor Cell-based therapeutics Market, 2018 - 2030 (USD Million)
    • 4.2.3.2. Autologous
    • 4.2.3.2.1. Autologous Market, 2018 - 2030 (USD Million)
    • 4.2.3.3. Allogenic
    • 4.2.3.3.1. Allogenic Market, 2018 - 2030 (USD Million)
    • 4.2.3.4. Others
    • 4.2.3.5. Others Market, 2018 - 2030 (USD Million)
  • 4.2.4. Cell-based Immunotherapies
    • 4.2.4.1. Cell-based Immunotherapies Market, 2018 - 2030 (USD Million)
  • 4.2.5. Gene Therapies
    • 4.2.5.1. Gene Therapies Market, 2018 - 2030 (USD Million)
• 4.3. Tools
  • 4.3.1. Tools Market, 2018 - 2030 (USD Million)
• 4.4. Banks
  • 4.4.1. Banks Market, 2018 - 2030 (USD Million)
• 4.5. Services
  • 4.5.1. Services Market, 2018 - 2030 (USD Million)

Chapter 5. Therapeutic Category Business Analysis

• 5.1. Global Regenerative Medicine Market: Therapeutic Category Movement Analysis
• 5.2. Dermatology
  • 5.2.1. Dermatology Market, 2018 - 2030 (USD Million)
• 5.3. Musculoskeletal
  • 5.3.1. Musculoskeletal Market, 2018 - 2030 (USD Million)
• 5.4. Immunology & Inflammation
  • 5.4.1. Immunology & Inflammation Market, 2018 - 2030 (USD Million)
• 5.5. Oncology
  • 5.5.1. Oncology Market, 2018 - 2030 (USD Million)
• 5.6. Cardiovascular
  • 5.6.1. Cardiovascular Market, 2018 - 2030 (USD Million)
• 5.7. Ophthalmology
  • 5.7.1. Ophthalmology Market, 2018 - 2030 (USD Million)
• 5.8. Others
  • 5.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Regional Business Analysis

• 6.1. Global Regenerative Medicine Market Share By Region, 2022 & 2030
• 6.2. North America
  • 6.2.1. North America Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.2.2. U.S.
    • 6.2.2.1. Key Country Dynamics
    • 6.2.2.2. Competitive Scenario
    • 6.2.2.3. Regulatory Framework
    • 6.2.2.4. Target Disease Prevalence
    • 6.2.2.5. U.S. Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.2.3. Canada
    • 6.2.3.1. Key Country Dynamics
    • 6.2.3.2. Competitive Scenario
    • 6.2.3.3. Regulatory Framework
    • 6.2.3.4. Target Disease Prevalence
    • 6.2.3.5. Canada Regenerative Medicine Market, 2018 - 2030 (USD Million)
• 6.3. Europe
  • 6.3.1. Europe Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.3.2. Germany
    • 6.3.2.1. Key Country Dynamics
    • 6.3.2.2. Competitive Scenario
    • 6.3.2.3. Regulatory Framework
    • 6.3.2.4. Target Disease Prevalence
    • 6.3.2.5. Germany Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.3.3. UK
    • 6.3.3.1. Key Country Dynamics
    • 6.3.3.2. Competitive Scenario
    • 6.3.3.3. Regulatory Framework
    • 6.3.3.4. Target Disease Prevalence
    • 6.3.3.5. UK Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.3.4. France
    • 6.3.4.1. Key Country Dynamics
    • 6.3.4.2. Competitive Scenario
    • 6.3.4.3. Regulatory Framework
    • 6.3.4.4. Target Disease Prevalence
    • 6.3.4.5. France Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.3.5. Italy
    • 6.3.5.1. Key Country Dynamics
    • 6.3.5.2. Competitive Scenario
    • 6.3.5.3. Regulatory Framework
    • 6.3.5.4. Target Disease Prevalence
    • 6.3.5.5. Italy Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.3.6. Spain
    • 6.3.6.1. Key Country Dynamics
    • 6.3.6.2. Competitive Scenario
    • 6.3.6.3. Regulatory Framework
    • 6.3.6.4. Target Disease Prevalence
    • 6.3.6.5. Spain Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.3.7. Denmark
    • 6.3.7.1. Key Country Dynamics
    • 6.3.7.2. Competitive Scenario
    • 6.3.7.3. Regulatory Framework
    • 6.3.7.4. Target Disease Prevalence
    • 6.3.7.5. Denmark Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.3.8. Sweden
    • 6.3.8.1. Key Country Dynamics
    • 6.3.8.2. Competitive Scenario
    • 6.3.8.3. Regulatory Framework
    • 6.3.8.4. Target Disease Prevalence
    • 6.3.8.5. Sweden Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.3.9. Norway
    • 6.3.9.1. Key Country Dynamics
    • 6.3.9.2. Competitive Scenario
    • 6.3.9.3. Regulatory Framework
    • 6.3.9.4. Target Disease Prevalence
    • 6.3.9.5. Norway Regenerative Medicine Market, 2018 - 2030 (USD Million)
• 6.4. Asia Pacific
  • 6.4.1. Asia Pacific Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.4.2. Japan
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Competitive Scenario
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. Target Disease Prevalence
    • 6.4.2.5. Japan Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.4.3. China
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Competitive Scenario
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Target Disease Prevalence
    • 6.4.3.5. China Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.4.4. India
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Competitive Scenario
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. Target Disease Prevalence
    • 6.4.4.5. India Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.4.5. South Korea
    • 6.4.5.1. Key Country Dynamics
    • 6.4.5.2. Competitive Scenario
    • 6.4.5.3. Regulatory Framework
    • 6.4.5.4. Target Disease Prevalence
    • 6.4.5.5. South Korea Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.4.6. Australia
    • 6.4.6.1. Key Country Dynamics
    • 6.4.6.2. Competitive Scenario
    • 6.4.6.3. Regulatory Framework
    • 6.4.6.4. Target Disease Prevalence
    • 6.4.6.5. Australia Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.4.7. Thailand
    • 6.4.7.1. Key Country Dynamics
    • 6.4.7.2. Competitive Scenario
    • 6.4.7.3. Regulatory Framework
    • 6.4.7.4. Target Disease Prevalence
    • 6.4.7.5. Thailand Regenerative Medicine Market, 2018 - 2030 (USD Million)
• 6.5. Latin America
  • 6.5.1. Latin America Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.5.2. Brazil
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Competitive Scenario
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Target Disease Prevalence
    • 6.5.2.5. Brazil Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.5.3. Mexico
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Competitive Scenario
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Target Disease Prevalence
    • 6.5.3.5. Mexico Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.5.4. Argentina
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Competitive Scenario
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Target Disease Prevalence
    • 6.5.4.5. Argentina Regenerative Medicine Market, 2018 - 2030 (USD Million)
• 6.6. MEA
  • 6.6.1. MEA Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.6.2. South Africa
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Competitive Scenario
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Target Disease Prevalence
    • 6.6.2.5. South Africa Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.6.3. Saudi Arabia
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Competitive Scenario
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Target Disease Prevalence
    • 6.6.3.5. Saudi Arabia Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.6.4. UAE
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Competitive Scenario
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Target Disease Prevalence
    • 6.6.4.5. UAE Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.6.5. Kuwait
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Competitive Scenario
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Target Disease Prevalence
    • 6.6.5.5. Kuwait Regenerative Medicine Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company Categorization
• 7.2. Strategy Mapping
• 7.3. Company Market/Position Share Analysis, 2022
• 7.4. Company Profiles/Listing
  • 7.4.1. AstraZeneca plc.
    • 7.4.1.1. Overview
    • 7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Strategic Initiatives
  • 7.4.2. F. Hoffmann-La Roche Ltd.
    • 7.4.2.1. Overview
    • 7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.2.3. Product Benchmarking
    • 7.4.2.4. Strategic Initiatives
  • 7.4.3. Integra Lifesciences Corp.
    • 7.4.3.1. Overview
    • 7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.3.3. Product Benchmarking
    • 7.4.3.4. Strategic Initiatives
  • 7.4.4. Astellas Pharma, Inc.
    • 7.4.4.1. Overview
    • 7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.4.3. Product Benchmarking
    • 7.4.4.4. Strategic Initiatives
  • 7.4.5. Cook Biotech, Inc.
    • 7.4.5.1. Overview
    • 7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.5.3. Product Benchmarking
    • 7.4.5.4. Strategic Initiatives
  • 7.4.6. Bayer AG
    • 7.4.6.1. Overview
    • 7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Strategic Initiatives
  • 7.4.7. Pfizer, Inc.
    • 7.4.7.1. Overview
    • 7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.7.3. Product Benchmarking
    • 7.4.7.4. Strategic Initiatives
  • 7.4.8. Merck KGaA
    • 7.4.8.1. Overview
    • 7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.8.3. Product Benchmarking
    • 7.4.8.4. Strategic Initiatives
  • 7.4.9. Abbott
    • 7.4.9.1. Overview
    • 7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.9.3. Product Benchmarking
    • 7.4.9.4. Strategic Initiatives
  • 7.4.10. Vericel Corp.
    • 7.4.10.1. Overview
    • 7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.10.3. Product Benchmarking
    • 7.4.10.4. Strategic Initiatives
  • 7.4.11. Novartis AG
    • 7.4.11.1. Overview
    • 7.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.11.3. Product Benchmarking
    • 7.4.11.4. Strategic Initiatives
  • 7.4.12. GlaxoSmithKline
    • 7.4.12.1. Overview
    • 7.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.12.3. Product Benchmarking
    • 7.4.12.4. Strategic Initiatives